Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.

The Medical journal of Australia - 17 Mar 2003

Kumar Dinesh, Wallington-Beddoe Craig, George Jacob, Lin Rita, Samarasinghe Dev, Liddle Chris, Farrell Geoffrey C

Abstract excerpt

AIM: To determine effectiveness of treatment for hepatitis C outside clinical trials, by testing the hypothesis that apparent effectiveness and tolerability of interferon alfa-2b/ribavirin combination therapy would be less in a hospital liver clinic setting. DESIGN: Retrospective analysis of all patients in one centre commencing interferon alfa-2b/ribavirin therapy, but not in clinical trials, between 1998 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C, Chronic

Share to Interferon-alpha

Share to Interferon alpha-2

Share to Recurrence

Share to Ribavirin

Source

Identifiers

PMID: 12633483
DOI: 10.5694/j.1326-5377.2003.tb05192.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Effectiveness of interferon alfa-2b/ribavirin combination therapy for chronic hepatitis C in a clinic setting.PMID 12633483Read ↗

Single centre experience with pegylated interferon and ribavirin for hepatitis C: looking back before moving forward.Semantic proximity Read ↗

Results of combination treatment with pegylated interferon and ribavirin in cirrhotic patients with hepatitis C infection.Semantic proximity Read ↗

Interferon alfa with or without ribavirin for chronic hepatitis C: systematic review of randomised trials.Semantic proximity Read ↗

Short versus standard treatment with pegylated interferon alfa-2A plus ribavirin in patients with hepatitis C virus genotype 2 or 3: the cleo trial.Semantic proximity Read ↗

A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3.Semantic proximity Read ↗

Outcome, tolerability and compliance of compassionate use interferon and ribavirin for hepatitis C infection in a shared care hospital clinic.Semantic proximity Read ↗

Combination therapy with interferon-alpha and ribavirin for hepatitis C: practical treatment issues.Semantic proximity Read ↗

From trials to a real hospital setting: effectiveness of pegylated interferon-alpha-2b/ribavirin combination therapy for naïve chronic hepatitis C patients.Semantic proximity Read ↗

Response to combination therapy in hepatitis virus C genotype 2 and 3.Semantic proximity Read ↗

Pilot study of pegylated interferon alfa-2b and ribavirin for recurrent hepatitis C after liver transplantation.Semantic proximity Read ↗

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)Semantic proximity Read ↗

Successful rescue therapy with only 4 weeks ribavirin monotherapy in end-stage cirrhosis due to genotype 2 chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.